Cells deficient in the nucleoside transporter hENT1 are highly resistant to gemcitabine17 and patients with pancreatic cancer who express low or undetectable levels of hENT1 have significantly lower median survival times than those with detectable levels18. This evidence concerns the gene SLC29A1 and pancreatic neoplasm.